Protalix BioTherapeutics, Inc.
News and overview for Protalix BioTherapeutics, Inc.
Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial
News-Medical.Net | 40 days 12 hours 44 minutes ago
Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO (taliglucerase alfa, previously referred to as prGCD) in treatment naive patients diagnosed with Gaucher disease.
Protalix reports positive Phase III trial results - MarketWatch
MarketWatch | 40 days 13 hours 32 minutes ago
PLX
Protalix BioTherapeutics to Present at the Oppenheimer 20th Annual Healthcare Conference [Press Release]
Business Wire | 26 days 12 hours 30 minutes ago
Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today that Dr. David Aviezer, President and CEO, will present at the Oppenheimer 20th Annual Healthcare Conference on Wednesday, November 4, 2009 at 1:35 PM ET. The conference is being held at the Waldorf Astoria Hotel in New York.
Protalix says Gaucher drug met goals in trial
Forbes | 40 days 12 hours 9 minutes ago
NEW YORK -- Protalix BioTherapeutics Inc. said Thursday a late-stage study of its Gaucher disease drug met its primary goals.
Protalix drug success puts new pressure on Genzyme
Forbes | 40 days 9 hours 5 minutes ago
* Company says drug could be approved in mid-2010 * Drug would compete with Genzyme ( GENZ - news - people )'s Cerezyme
CORRECTING and REPLACING Protalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO for the Treatment of Gaucher Disease [Press Release]
Business Wire | 40 days 11 hours 22 minutes ago
Fourth graph should read: Statistically significant improvements compared with baselines were observed in hemoglobin level and liver size and significant nominal elevation in platelet count in the lower dose of 30 U/kg (sted significant nominal reduction in platelet count).
Zacks Bull and Bear of the Day Highlights: Sealed Air Corporation, Hologic, Inc., Genzyme Corp., Shire plc and Protalix BioTherapeutics Inc. [Press Release]
Business Wire | 7 days 2 hours ago
Zacks Equity Research highlights Sealed Air Corporation (NYSE: SEE) as the Bull of the Day and Hologic, Inc. (Nasdaq: HOLX) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Genzyme Corp. (Nasdaq: GENZ), Shire plc (Nasdaq: SHPGY) and Protalix BioTherapeutics Inc. (AMEX: PLX).
Zacks Analyst Blog Highlights: US Bancorp, Visa Inc., Genzyme Corp, Shire plc and Protalix BioTherapeutics Inc. [Press Release]
Business Wire | 33 days 3 hours ago
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: US Bancorp (NYSE: USB), Visa Inc. (NYSE: V), Genzyme Corp (Nasdaq: GENZ), Shire plc (Nasdaq: SHPGY) and Protalix BioTherapeutics Inc. (NYSE: PLX). Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at...
Drug stocks edge up; BioCryst soars on flu news - MarketWatch
MarketWatch | 29 days 9 hours 15 minutes ago
Shares of BioCryst /quotes/comstock/15*!bcrx/quotes/nls/bcrx (BCRX 10.95, +1.29, +13.35%) shot up 15% to $11.19.
Thursday's biggest gaining and declining stocks - MarketWatch
MarketWatch | 40 days 12 hours 6 minutes ago
The health of big business -- and the rebound in the stock market -- may be blinding us to just how weak the rest of the economy is.
UPDATE 2-Protalix Gaucher drug successful in clinical trial
Forbes | 40 days 9 hours 5 minutes ago
By Toni Clarke BOSTON, Oct 15 (Reuters) - The Israeli biotechnology company Protalix Biotherapeutics Inc said on Thursday that its experimental drug to treat Gaucher disease, a rare genetic disorder, was successful in a late-stage clinical trial.
Canaccord Adams hosts 29th Annual Global Growth Conference: August 11-13, 2009: Boston [Press Release]
PRNewswire | 110 days 3 hours 59 minutes ago
- Investor conference features 240 small and mid-cap companies in six sectors - - 50+ next-generation companies will present at the Private Company Showcase - - Knowledge sessions will feature key topics in targeted coverage areas -
Bank of Hawaii, Synovus, Lorillard, Protalix, SuperGen: U.S. Equity Movers
Bloomberg | 29 days 2 hours 49 minutes ago
Oct. 26 (Bloomberg) -- Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses and stock prices are as of 4 p.m. in New York.
Atlas, Bank of America, Protalix, Sohu.com, SuperGen: U.S. Equity Movers
Bloomberg | 29 days 7 hours 49 minutes ago
Oct. 26 (Bloomberg) -- Shares of the following companies are having unusual moves in U.S. trading. Stock symbols are in parentheses and stock prices are as of 11:20 a.m. in New York.
Steel, rubber found in some Genzyme drugs
Forbes | 10 days 23 hours 44 minutes ago
* Particles found in less than 1 pct of affected drugs * Potential for adverse reactions but none reportedArticle Controlsemail
Sign up for NRF Global SmartBrief
Company Overview
| Company: | Protalix BioTherapeutics, Inc. |
|---|---|
| Industry: | Biopharmaceuticals & Biotherapeutics |
| Website: | http://www.protalix.com |
What do you get when you cross a petunia with a person? Protalix BioTherapeutics hopes that whatever it is, it cures or prevents diseases. The biotech firm is splicing human DNA into plant cells and growing active proteins, including monoclonal antibodies and enzymes, that it hopes can turn into drug candidates. The company's lead product, UPLYSO, is an enzyme replacement therapy for Gaucher Disease. Already granted orphan drug status the by FDA, the drug is in late-stage clinical trials. Other product candidates include treatments for specialty diseases including Fabry disease.
Key Numbers
| Sales in U.S. Dollars (mil.) | 0 (2008) |
|---|---|
| One-year % Growth in Sales | 0.0 (2008) |
| Net Income in U.S. Dollars (mil.) | -22.4 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 0 (0) |
| One-year % Growth in Number of Employees | 0.0 (0) |
| Fiscal Year-End | December |